Condition: Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Mixed Phenotype Acute Leukemia · Sponsor: Meryx, Inc.
This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia. Patients will receive continuous oral MRX-2843 in 28 day cycles at predefined dose cohorts.
This description comes directly from the study's public registry record.
Meryx · 919-270-4667 · safety@meryxpharma.com
Always discuss trial participation with your own doctor first.
| Emory University - WINSHIP Cancer Center | Atlanta, Georgia, United States | Recruiting |
| Emory University, Children's Healthcare of Atlanta | Atlanta, Georgia, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04872478